Plandaí Biotechnology, Inc. (OTCQB: PLPL), a producer of highly bioavailable plant extracts for industries including health, wellness, nutraceutical, and pharmaceutical, today released a comparative review of its Phytofare™ Catechin Complex against a previous green tea study sponsored by Nu Skin. Plandaí recently announced favorable results from an anti-aging study of its Phytofare™ in a topical solution.
A study published in 2005 in volume 31 of Dermatologic Surgery and sponsored by Nu Skin International addressed the positive histological and clinical effects that green tea in a topical formulation has on characteristics of photoaging. The study focused on fine wrinkling, tactile roughness, visual dryness, and skin laxity/tone. The eight-week study concluded that histologic grading found improvement; however, clinically significant changes could not be visually observed, suggesting that clinically visible improvements in the skin may take longer supplementation to achieve. What this means in simple terms is that while structural improvements were noted, these changes were not visibly apparent on the surface of the skin.
The Plandaí study completed by North West University, South Africa not only validates what the Nu Skin study proved, histologically, but goes a step further and proves statistically and significantly that Plandaí's Phytofare™ Catechin Complex also delivers visible anti-aging benefits in only six weeks. This was clearly shown in the results of 3 of the 4 areas that were tested:
-Skin hydration - 15.2% increase as compared to the baseline
-Skin roughness - 14.6% decrease as compared to the baseline
-Skin scaliness - 20.4% reduction as compared to the baseline
The results for skin elasticity were not statistically significant, which is in line with the Nu Skin study results. Callum Baylis-Duffield, Vice President of Sales for Plandai, explained, "When discussing anti-aging, we want to look at both visible changes and histological changes. In other words, what is happening on the surface and what is happening to skin structures below the surface. In the case of collagen production, this can take three months or longer before this remodeled tissue reaches the surface and becomes visible. It is therefore not surprising that skin biopsies showed that improvement was taking place in the skin structure.
"Plandaí, however, has been able to take it one step further and also demonstrate immediate visible results," Mr. Baylis-Duffield continued. "Phytofare™, which is a highly bioavailable version of green tea catechins, has demonstrably superior anti-oxidant absorption. This means that we can generate both noticeable and histologic results, yielding immediate and long-term anti-aging benefits."
Plandaí has announced that both topical and oral formulations of its Phytofare™ Catechin Complex entrapped in Pheroid® (Ph2) will be available as an ingredient to customers starting summer 2014.
About Plandaí Biotechnology, Inc.
Plandaí Biotechnology, Inc. and its subsidiaries develop highly bioavailable, phytonutrient rich extracts which are being utilized to deliver a new family of drugs to safely and affordably treat a multitude of diseases and conditions. Plandaí Biotechnology controls every aspect of the process, from growing the raw materials on its farms in South Africa, to producing its patented Phytofare™ extracts in-house, allowing the Company to guarantee the continuity of supply as well as quality control throughout the entire process. Targeted industries for the Company's products include beverage, cosmeceutical, wellness, nutraceutical, anti-aging, and pharmaceutical. For more information, please visithttp://www.plandaibiotech.com.
Safe Harbor Statement
The information provided may contain forward-looking statements and involve risks and uncertainties. Results, events and performances could vary from those contemplated. These statements involve risks and uncertainties which may cause actual results, expressed or implied, to differ from predicted outcomes. Risks and uncertainties include product demand, market competition, and Plandaí's ability to meet current or future plans. Investors should study and understand all risks before making an investment decision. Readers are recommended not to place undue reliance on forward-looking statements or information. Plandaí is not obliged to publicly release revisions to any forward-looking statement, to reflect events or circumstances afterward, or to disclose unanticipated occurrences, except as required under applicable laws.
SOURCE: Plandai Biotechnology, Inc.